Table 3 |
||||
|
Baseline characteristics of treatment groups |
||||
|
Placebo |
Group A |
Group B |
Group C |
|
|
|
||||
|
N completed (started) |
23 (29) |
20 (25) |
22 (24) |
26 (29) |
|
Age (years) |
51.3 ± 1.0 |
50.5 ± 1.7 |
52.3 ± 1.8 |
52.1 ± 1.6 |
|
Gender (F: M %) |
72:28 |
76:24 |
75:25 |
52:48 |
|
ARA Functional Class II/III, % |
69 : 31 |
76 : 24 |
67 : 33 |
69 : 31 |
|
Kellgren Lawrence Criteria Grade 2/3, % |
76 : 24 |
83 : 17 |
83 : 17 |
82 : 18 |
|
WOMAC A |
8.7 ± 1.0 |
9.1 ± 1.2 |
8.0 ± 1.1 |
8.7 ± 1.0 |
|
WOMAC B |
3.4 ± 0.5 |
3.5 ± 0.5 |
3.3 ± 0.4 |
3.3 ± 0.4 |
|
WOMAC C |
36.4 ± 3.9 |
38.4 ± 4.0 |
34.7 ± 4.2 |
32.8 ± 4.3 |
|
WOMAC Total |
48.6 ± 5.2 |
51.1 ± 6.4 |
46.4 ± 5.6 |
44.8 ± 5.5 |
|
VAS |
72.9 ± 2.0 |
72.9 ± 3.0 |
70.1 ± 2.5 |
70.7 ± 2.4 |
|
|
||||
|
Data expressed as a % of total or mean ± sem. Group A = High dose sierrasil, Group B = Low dose sierrasil, Group C = Low dose sierrasil + cat's claw extract. None of the entry assessments were significantly different amongst the four randomized groups. |
||||
|
Miller et al. Journal of Inflammation 2005 2:11 doi:10.1186/1476-9255-2-11 |
||||
